Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Another Crisis For...

    Another Crisis For Fortis: IHH audit committee Chief opposes deal

    Written by Ruby Khatun Khatun Published On 2018-07-24T15:04:11+05:30  |  Updated On 24 July 2018 3:04 PM IST
    Another Crisis For Fortis: IHH audit committee Chief opposes deal

    New Delhi: The planned acquisition of Fortis for Rs 4000 crores by IHH has now landed in another crisis as an independent non-executive director of IHH Healthcare had opposed the deal pointing it out risky.


    ET reports that an independent non-executive director, who is also the Chairman of the audit and risk management committee of IHH opposed the planned acquisition of a controlling stake in Fortis Healthcare.


    Medical dialogues had earlier reported that Fortis board had unanimously accepted a binding offer from Malaysia’s IHH Healthcare Berhad to invest Rs 4,000 crore in it by way of preferential allotment at Rs 170 per share.


    Read also: IHH Healthcare: Meet the Highest Bidder of Fortis Healthcare


    All in all, IHH Healthcare is expected to shell out a total of Rs 7,300 crore to acquire a 57.1% stake, provided its open offer for 26 percent stake is fully subscribed. The Malaysian healthcare chain, which will gain majority control of India’s second-largest hospital chain, has already stated that in the long term it will rebrand Fortis hospitals into its own Gleneagles chain.


    Read also: Fortis to be renamed as Gleneagles, says IHH Managing Director Tan See Leng


    In a recent report, ET has reported that the opposition has come from Rossana Annizah Binti Ahmad Rashid, who is the independent non-executive director on the 11-member board and she made her dissent official in the meeting that approved the deal.


    She is also chairman of the audit and risk management committee and a member of the nomination and remuneration committee of the board so her view is important.


    ET reports that She “was not comfortable with the structure of the proposals after taking into consideration the risk factors related to the proposals and the qualified opinion issued by Fortis’ external auditors, Deloitte Haskins and Sells LLP, in the audited financial statements of Fortis for the year ended March 31.”


    An IHH spokesperson told ET, “The board evaluated various factors to ensure a fair decision. One director concluded with a differing viewpoint. The final decision was taken by a majority, as per regulations, and the dissent was taken on record. As we understand, there is no connection between the view taken by an individual director of IHH and the forthcoming EGM (extraordinary general meeting) of Fortis as referred to by you.”


    The Fortis EGM will be held on 13 August to seek shareholders vote for its acquisition by Malaysia’s IHH Healthcare.


    Read also: Fortis EGM on 13 August over stake sale to IHH

    Acquisitionaudit committeebuychiefDeloitte HaskinsDeloitte Haskins and Sells LLPEGMextraordinary general meetingFortisFortis boardFortis HealthcareFortis HospitalsIHHIHH HealthcareIHH Healthcare BerhadIHH Healthcare Bhdindependent non-executive directorMalaysia's IHH Healthcare Bhdopposedrisky
    Source : With Inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok